Despite a great variety of molecules used in several diabetes animal models to reduce NLRP3/AIM2 inflammasome activation (Figure 1), and hence, to prevent cardiac injury, clinical trials are still required to study the possible benefit of NRLP3 targeted therapies in humans. Here, NLRP3 is linked to diabetes mellitus.